Fieldpoint Private Securities’s Charles River Laboratories CRL Stock Holding History

Fieldpoint Private Securities’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$3K	Sell	15 -45	-75%	-$11K	﹤0.01%	1029
2022 Q1	$17K	Buy	60 +5	+9%	+$1.54K	﹤0.01%	888
2021 Q4	$21K	Hold	55	–	–	﹤0.01%	859
2021 Q3	$23K	Hold	55	–	–	0.01%	785
2021 Q2	$22K	Hold	55	–	–	﹤0.01%	777
2021 Q1	$16K	Buy	55 +5	+10%	+$1.39K	﹤0.01%	847
2020 Q4	$12K	Buy	+50	New	+$11.9K	﹤0.01%	842

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldpoint Private Securities's CRL Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Charles River Laboratories (CRL) stake by 75% in Q2 2022, selling an estimated $11K and leaving 15 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Fieldpoint Private Securities first reported a position in CRL in Q4 2020 and has held it in 7 quarters since. The position peaked at $23K in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

Fieldpoint Private Securities held 15 shares of Charles River Laboratories worth $3K as of Q2 2022.
Fieldpoint Private Securities sold 45 Charles River Laboratories shares in Q2 2022, an estimated $11K.
Charles River Laboratories made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1029 holding.
Fieldpoint Private Securities first reported a position in Charles River Laboratories in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Charles River Laboratories position peaked at $23K in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.